Endocrinology

Berry discussed findings from a retrospective, real-world study but emphasized that they should be confirmed in randomized controlled trials.

Explore the urgent need for diabetes specialists and the American College of Diabetology's efforts to enhance care through education and certification.

Hosts sit down for a deep dive into The Diabetes Collective and what it's like operating a diabetes clinic in the modern healthcare landscape.

A recent cross-sectional analysis has estimated the size of the American population with both MASLD and T2DM eligible for treatment.

Verma went over the STRIDE trial evaluating the GLP-1 RA and its latest findings presented at ADA Scientific Sessions.

Discover how the CATALYST trial reveals mifepristone's potential to enhance glycemic control and weight loss in challenging type 2 diabetes cases.

Mifepristone shows promise in improving glycemic control and reducing weight in patients with hypercortisolism and type 2 diabetes.

Maridebart cafraglutide shows potential as a monthly treatment for obesity and type 2 diabetes, demonstrating significant weight loss and glycemic improvements.

Explore groundbreaking findings from the REDEFINE trials on CagriSema's impact on weight loss and diabetes management at ADA 2025.

Kevin Sayer joins the program to discuss the latest from Dexcom and preview where the business is headed in an evolving diabetes landscape.

A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes.

A global study reveals that universal access to semaglutide could save 28 million lives and significantly reduce obesity and diabetes worldwide.

CagriSema shows weight loss results in recent trials comparable to existing interventions.

A phase 3 trial reveals ecnoglutide significantly reduces body weight in overweight patients, showcasing its potential as a novel obesity treatment.

New findings reveal semaglutide significantly enhances walking ability and quality of life for patients with T2D and PAD.

A new study reveals hybrid closed-loop technology significantly improves glucose control for pregnant women with T1D.

Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.

The ACHIEVE-1 trial reveals orforglipron's potential as a breakthrough treatment for type 2 diabetes.

New research reveals amycretin's promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options.

Most participants (83%) did not require exogenous insulin 1 year after zimislecel (VX-880) infusion.

An overview of 7 presentations included as late-breaking clinical trials at ADA 2025.

Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.

Martin reviews recent trends in cardiovascular disease and contributing underlying risk factors, describing them as a “call to action” for cardiovascular care.

Lopez discusses the evolving understanding of the utility of SGLT2 inhibitors and GLP-1 RAs in heart failure care, including both HFpEF and HFrEF.

Incretin-based therapies for obesity and diabetes may be capable of treating a much wider range of diseases, including Alzheimer’s and Parkinson’s.